A Randomized, Open-label, Single Dose, Two-way Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR3003 and Co-administration of BR3003B and BR3003C in Healthy Volunteers.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of BR3003 and co-administration of BR3003B and BR3003C in healthy adults.